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ABSTRACT Disruption of latent Epstein-Barr virus
(EBV) infection is induced by the key immediate-early protein
BZLF1 (or Z, a member of the basic leucine-zipper family),
which transactivates the viral early promoters. Viral reactiva-
tion is marked by renewed synthesis of early gene products such
as EBV early antigen-diffuse (EA-D). Retinoic acid has been
previously shown to inhibit reactivation of EBV infection.
Retinoic acid responsive receptors are known to act as posi-
tively regulating transcription factors but can also negatively
regulate AP-1 responsive genes. Here we demonstrate that the
retinoic acid receptor a (RARa) and retinoid X receptor a
(RXRa) inhibit the ability of the Z protein to transactivate the
viral early promoter BMRF1, which directs transcription of
EA-D. Z can also reciprocally inhibit RARa- and RXRa-
induced activation of an autoregulated cellular promoter for
the RARI3 gene (BRE) through a non-DNA binding mecha-
nism. RXRa inhibits Z from binding to the AP-1 motif in the
BMRF1 promoter and, reciprocally, Z inhibits RARa from
binding to its retinoic acid response element in the BRE
promoter. Furthermore, a glutathione-S-transferase-RXRa
fusion protein can interact directly with the Z protein. These
results suggest that a direct protein-protein interaction be-
tween Z (the viral protein) and RARa and RXRa (cellular
proteins) can modulate the reactivation of latent EBV infection.
Epstein-Barr virus (EBV), the causative agent of infectious
mononucleosis, exists in cells either as a latent infection or in
a cytolytic virus-productive state. Infection of B lympho-
cytes is predominantly latent, whereas infection in mucosal
epithelial cells of the oropharynx is characterized by cytol-
ysis and viral replication (1). The switch from latency to the
virus-productive state is induced by a variety of agents such
as phorbol esters, sodium butyrate, calcium ionophores, and
anti-immunoglobulins (for review, see ref. 2), all of which
activate Z, the EBV immediate-early gene product, which is
sufficient to trigger disruption of viral latency in EBV-in-
fected cells. Z, a member of the basic leucine-zipper family,
transactivates several early viral promoters required in the
cytolytic cycle of the virus. Transcriptional activation of
early EBV promoters by Z requires upstream Z-binding sites
(called Z-response elements) that are similar (and sometimes
identical) to AP-1 sites (for review, see ref. 2). Cellular
factors may also interact with Z in promoting or modulating
the reactivation of the latent infection.
BMRF1, the EBV early promoter, which governs tran-
scription of early replicative antigens [early antigen-diffuse
(EA-D)], has an AP-1-binding site that is transactivated by Z
much more efficiently in some cell lines (such as HeLa) than
others (such as Jurkat and Louckes) (3). Lack of efficient
transactivation in certain cell lines could be due to a require-
ment for a cellular factor that synergistically activates the
promoter with Z. For example, the cellular oncogene, c-myb,
interacts synergistically with Z in lymphoid cells to transac-
tivate early promoter(s) (4). Alternatively, some cellular
factor may negatively regulate Z transactivation of the
BMRF1 promoter.
Retinoic acid (RA) can inhibit the phorbol ester induction
of EA-D (5) and EBV DNA synthesis (6); however, the
mechanism of inhibition was obscure. RA, retinol (vitamin
A), and other retinoids exert striking effects on cell prolifer-
ation and differentiation, inhibit growth of some malignant
cells, and inhibit invasiveness of metastatic cells (7, 8). These
ligands, which are abundant in serum, are removed by
charcoal treatment and mediate their effect through a family
of RA receptors (RARs), which are ligand-dependent tran-
scription factors (9, 10). RARs stimulate gene transcription
by binding to DNA motifs termed RA response elements
(RAREs) that are found in promoter regions of numerous
genes (11, 12). RARs are members of the steroid hormone
receptor superfamily and are divided into two classes, each
having at least three isoforms: RARa, -Is, and -y (13-15) and
retinoid X receptors (RXRa, -P3, and -y) (16, 17). The recep-
tors are also negative regulators of several genes although
less is known about the mechanism of this effect (18-21).
Here we report that the mechanism for inhibition of viral
reactivation by RA appears to be interference with the action
of the Z protein. Z transactivation of an EBV early promoter
is abrogated by RA, and this effect is mediated through RXRa
and RARa. In this study, we have used the BMRF1 promoter,
which has a RARE adjacent to an AP-1 site. The BMRF1
promoter is transactivated very efficiently by Z in Louckes, a
lymphocyte line, when grown in medium containing charcoal-
stripped serum (CSS), but transactivation is repressed by
coexpression with RAR plasmids. The mechanism of repres-
sion is at least partially through a non-DNA-binding mecha-
nism, although the receptors can bind specifically to the RARE
in the viral promoter. Furthermore, the viral protein recipro-
cally down-regulates RXRa- and RARa-mediated induction of
an autoregulated cellular promoter (BRE) for a RAR gene
(RAR/3) by interfering with the binding of the RARs to their
cognate binding site in the promoter. These data suggest that
Z (the viral protein) and RXRa and RARa (the cellular
proteins) may reciprocally modulate their respective transac-
tivation effects through protein-protein interaction.
MATERIALS AND METHODS
Recombinant Plasmids. The BMRF1 promoter construct
(BMRF1-CAT; where CAT is chloramphenicol acetyltrans-
Abbreviations: EBV, Epstein-Barr virus; RA, retinoic acid; RAR,
RA receptor; EA-D, early antigen-diffuse; RXR, retinoid X receptor;
CAT, chloramphenicol acetyltransferase; CSS, charcoal-stripped
serum; GST, glutathione S-transferase; RARE, RA response ele-
ment.
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ferase) and the Z expression clone (pEBV-ZIE) have been
described (3). The plasmid ARRE-CAT (formerly referred to
as pEAAMYB-CAT) was constructed by site-directed muta-
genesis of the RARE site in BMRF1-CAT (4). Clones
pRshRARa (12), pRshRXRa (16), pBRE-CAT (11), and
pGEX-RXRa (16) and the vector pFlag (22) were as de-
scribed. pFL-Z and pGEX-Z constructs were generous gifts
of Q. Zhang and D. Gutsch (University of North Carolina,
Chapel Hill).
Transfections and Reporter Assays. Transfections were
done as described (23). Twenty-four hours before transfec-
tion, cells were transferred to phenol red-free RPMI 1640
medium supplemented with 5% (vol/vol) CSS. Transfections
were done in RPMI 1640 medium and 10% (vol/vol) fetal calf
serum, and cells were then refed with medium containing 5%
CSS. RA (1 ,uM) was added 24 h after transfection. Cell
extracts were harvested 24 h later and assayed for CAT
activity (24) by using 60 ,ug of total cell extract protein. All
experiments were repeated three or more times.
Transfection of plasmid DNA into COS cells was done
using DEAE-dextran coprecipitation (25). Cell extracts were
prepared after 48 h and lysed in buffer containing 50 mM
Hepes (pH 7.0), 250 mM NaCl, 0.1% Nonidet P-40, 5 mM
EDTA, 5 mM dithiothreitol, and 1 mM phenylmethylsulfonyl
fluoride. These extracts were used as protein sources for
RXRa and RARa in mobility-shift assays.
Bacterial Expression ofZ and RXRa. The pFL-Z construct
was derived by cloning the Z coding sequence (in-frame)
downstream of the Ml epitope in a modified pFlag vector
(IBI) (22). The glutathione-S-transferase-RXRa (GST-
RXRa) fusion protein was expressed and purified from
glutathione-Sepharose beads (16). The pGEX-Z construct
was obtained by inserting the Z coding sequence downstream
of GST in the pGEX-3X vector (Pharmacia). The GST-Z
fusion protein was derived by transforming Escherichia coli
BL21DE3-pLysS with the clone and inducing from midlog-
arithmic phase with 0.1 mM isopropyl f3-D-thiogalactoside for
1 h at 30°C. Lysates were made by sonicating 10 ml of
bacterial cultures and incubated with glutathione-Sepharose
beads, followed by washing three times with phosphate-
buffered saline and then twice with reaction buffer (20 mM
Hepes/80 mM KCI/0.05% Nonidet P40/0.2 mM dithiothrei-
tol).
DNA-Binding Studies. A 33-bp internally 32P-labeled oligo-
nucleotide, EaD (5'-CACCATGCTGGTAGATGACCTT-
TGAGTCAGGGT-3'), containing the BMRF1 sequence span-
ning the adjacent RARE and AP-1 sites, was used as a probe
and incubated with 5 ,ul of in vitro-translated Z protein. Z
binding reactions were as described (4). RXRa- and RARa-
binding assays were performed by incubating proteins in
binding buffer (26) at room temperature for 20 min with 1 ng
of a 42-bp internally 32P-labeled [32p] oligonucleotide contain-
ing BRE sequences spanning a functional RARE (BRE probe)
(5'-AAGGGGATCCGGGTAGGGTTCACCGAAAGT-
TCACTC-3') added to the reaction mixture and incubated
further for 10 min.
RESULTS
Repression by RXR of Z-Mediated Transactivation of an
EBV Early Promoter. The BMRF1 promoter (Fig. 1A) linked
to the CAT reporter gene is strongly transactivated by Z in
HeLa cells, but its activity is only slightly increased in
lymphoid cell lines, Louckes and Jurkat (3). However, if
these cells are grown in medium containing CSS, the BMRF1
promoter can be efficiently transactivated by Z (Fig. 1B).
These results suggest that a depletable factor in the serum
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FIG. 1. (A) Schematic of the EBV early promoter BMRF1. The
arrow indicates the transcription start site. A "TATA" box is located
at position -32, and an AP-1 site is at position -64. A RARE is
adjacent to the AP-1 site. (B) RXRa and RARa repress Z induction
of the BMRF1 promoter. The BMRF1 promoter-CAT construct (5
,ug) was cotransfected into Louckes cells with vector DNA
(pHD1013) (bar 1), pEBV-ZIE (0.1 ,ug) (bar 2), or the combination of
pEBV-ZIE and the RAR (pRshRARa) or RXR (pRshRXRa) expres-
sion vector (3 tg) (bars 3 or 4, respectively) or all three (bar 5). A
construct containing the cellular promoter for RAR,8 (BRE-CAT) (5
,ug) (bar 6), which contains a canonical RARE element, was used as
a positive control for RXRa (bar 7) and RARa (bar 8) induction. The
total DNA input was kept constant by using the plasmid pHD1013.
RA was added 24 h after transfection. CAT assays were performed
and data are presented as fold activation.
Cross-coupling or interaction of distinct families of tran-
scription factors has been demonstrated (27, 28). Members of
the steroid hormone receptor superfamily interact with the
AP-1 (27) and OTF-1 transcription factors (28); both gluco-
corticoid receptor and RAR interact with AP-1 (27). Since the
Z gene product contains significant similarity to the DNA
binding domain of c-fos (a component of the AP-1 complex),
we examined the functional interactions between Z and the
RARs. When the BMRF1-CAT construct was cotransfected
into Louckes cells with pRshRXRa or pRshRARa, consti-
tutive BMRF1-CAT activity was unaffected (data not
shown). However, when BMRF1-CAT was cotransfected
with pEBV-ZIE and either pRshRXRa or pRshRARa, there
was significant repression of Z-induced transactivation (Fig.
1B). The combination of RARa and RXRa produced the
greatest repression of Z transactivation. In contrast the
control plasmid BRE-CAT, which contains a RARE from the
promoter for the RAR,8 receptor, was induced by RA. In
control experiments, the cytomegalovirus immediate-early
promoter activity (CMVIE-CAT) was not repressed by
pRshRXRa, which indicates that RXRa does not exert its
repressive effect by reducing the expression of the CMVIE
promoter-driven Z-expression clone.
Role of the RARE Site in the BMRF1 Promoter. The
BMRF1 promoter contains a consensus RARE site located
immediately adjacent to the AP-1 site (Fig. 1A). To determine
whether RARs recognize this sequence, a 33-bp oligonucle-
otide (EaD probe) spanning the RARE site and the AP-1 site
in the BMRF1 promoter was used in protein binding assays.
Both EaD and BRE probes produced a complex with re-
tarded mobility that was more prominent with the RXRa-
transfected COS-cell extract than with mock-transfected
extract (Fig. 2 A and B, lanes 1 and 2). RARa-transfected
COS-cell extract also produced a distinct complex with the
EaD probe (data not shown). The mock-transfected extracts,
as expected, contain a small amount of endogenous RAR
binding activity. Formation of the complex with the EaD
probe was inhibited by unlabeled BRE (Fig. 2A, lane 4) and
EaD probes (lanes 3 and 8), whereas oligonucleotides con-
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FIG. 2. RXRa binds specifically to the BMRF-1 promoter.
Mock-, RXRa-, or RARa-transfected COS cell extracts (5 ug) were
used as a source of proteins. Mobility-shift assays were done using
32P-labeled EaD (A) or BRE (B) probes. For competition with
unlabeled oligonucleotides, a 100-fold molar excess of competitors
AP-1 (5'-CGCTTGATGAGTCAGCCGGAA-3'), Oct (5'-TGTC-
GAATGCAAATCACTAGAA-3'), RRE (5'-CACCATGCTGGTA-
GAAGGCCTTTGAGTCAGGGT-3'), EaD, and BRE were added to
the reaction mixture before addition of the probe. Protein-DNA
complexes were resolved by PAGE on 5% gels in 0.5 x TBE (1 x TBE
= 0.09 M Tris borate/0.002 M EDTA) and the dried gel was exposed
with an intensifying screen at -70°C to Kodak XAR film. (A) Lanes:
1, mock-transfected cells; 2-8, RXRa-transfected cells; 9, free
probe; 1, 2, 9, no competitor; 3-8, competitors EaD, BRE, AP-1,
Oct, RRE, and EaD, respectively. (B) Lanes: 1, mock-transfected
cells; 2, RXRa-transfected cells.
taining the AP-1 and Oct sites (Fig. 2A, lane 5 and 6,
respectively) did not compete. Furthermore, an oligonucle-
otide sequence identical to the EaD probe except for muta-
tion of the RARE sequence (RRE, Fig. 2A, lane 7) could not
compete with the EaD probe. In addition, both unlabeled
EaD and BRE competed for binding to the BRE probe (data
not shown). These data suggest that the BMRF1 promoter
contains a functional RARE motif that can be bound by both
RXRa and RARa.
Since the AP-1 and RARE sites are adjacent, repression
could be the result of steric hindrance of the receptor binding
to the RARE, making the AP-1 site inaccessible to Z. To
determine whether the RARE in the BMRF1 promoter con-
tributes to RXRa-induced repression of Z transactivation,
the effect of site-directed mutations that specifically abol-
ished the RARE site (ARRE-CAT) was tested. There was
85% repression of BMRF1-CAT activity even after the
RARE site was mutated (Fig. 3), suggesting that additional
RARE sites upstream may be involved in repression or, as
subsequent results indicated, that RAR-mediated repression
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FIG. 3. RARE site is not required for RXRa repression of
Z-mediated induction of the BMRF1 promoter. The BMRF1 pro-
moter construct ARRE-CAT, in which the RARE site has been
abolished, was cotransfected with vector DNA (5 pg) (bar 1), the
pEBV-ZIE (0.1 /,g) (bar 2), or the combination of Z and pRshRXRa
(3 pg) (bar 3) into Louckes cells. BRE-CAT (bar 4) was transacti-
vated by RXRa (bar 5). Bar 6 shows RSVCAT activity. RA was
added 24 h after transfection. CAT activity was assayed and pre-
sented as percent acetylation.
is mediated by a protein-protein interaction between Z and
RXRa.
Reciprocal Down-Regulation ofa Cellular Promoter Respon-
sive to RA by the Viral Transactivator Z. RAREs are located
upstream of the RNA start site in the promoter for RARf3,
which is autoregulated (11). When a construct containing the
RARj3 promoter (BRE-CAT) is cotransfected with any of the
RARs (RARa, -,(, -y and RXRa) in the presence of RA, an
increase in promoter activity results (11, 17). To determine
whether Z interacts with the RARs directly, pEBV-ZIE was
cotransfected with pRshRXRa. As shown in Fig. 4A, RXRa
induced activity of the BRE-CAT construct 28-fold upon RA
addition. Z alone had no effect on the RARP promoter (data
not shown). However, when both RXRa and Z were ex-
pressed, only a 2.4-fold increase in activity was detected. Z
could also repress the induction of BRE-CAT promoter
activity mediated by RARa (Fig. 4B) or RAR'y (data not
shown). Furthermore, a mutant of Z, Z311 (13) (a gift from A.
Sergeant, Ecole Normale Superiurede Lyon, Lyon, France),
that contains a point mutation in the basic DNA-binding
domain could still repress the RAR/RXR-mediated induction
of BRE-CAT (Fig. 4A), suggesting that Z and the receptors
may interact directly or through an intermediary protein. All
the RARs were cloned downstream of the Rous sarcoma
virus (RSV) long terminal repeat promoter; in control exper-
iments, RSV-CAT activity was not repressed by cotransfec-
tion with Z.
DNA Binding of Z to the BRE Promoter Is Not Required for
its Repression. Although functional studies indicated Z311
could still repress RAR-induced activation of BRE-CAT, it
was nevertheless possible that Z could bind directly to the
RAR13 promoter. Mobility-shift assays indicated that the Z
protein did not bind to BRE probe although as expected it
.. ..,
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FIG. 4. (A) Z represses RXRa-mediated transactivation. The pBRE-CAT construct containing the RARE from the RAR,3 promoter (5 pUg)
was transfected into Louckes cells (bar 1) or cotransfected into Louckes cells with pRshRXRa (3 ug) (bar 2), the combination of pRshRXRa
and pEBV-ZIE (5 ,tg) (bar 3), or the combination of pRshRXRa and a Z mutant (Z311, which is unable to bind DNA) (5 j±g) (bar 4). Transfected
cells were treated with either ethanol or RA, harvested 24 h later, and assayed for CAT activity. (B) Z also represses RARa-mediated
transactivation. BRE-CAT was transfected (bar 1) or cotransfected with the pRshRARa (3 ,Ag) (bar 2) or the combination of pRshRARa and
pEBV-ZIE (0.1 ,ug) (bar 3) into Louckes cells. (C) Z does not bind to the cellular promoter RAR,8. Mobility-shift assays were done using the
BRE (lane 1) and EaD (lanes 2-4) probes. The Z protein was transcribed and translated in vitro by using wheat-germ lysate from the SP64 vector
containing Z cDNA (9); wheat-germ lysate was used as a control. Lanes: 1 and 3, Z protein; 2, wheat-germ lysate; 4, no protein. Arrow indicates
Z binding to the EaD probe.
3896 Cell Biology: Sista et al.








FIG. 5. (A) Z abolishes RARa binding to the RAR,8 promoter.
Mobility-shift assays were done using the BRE probe and mock (lane
1) or RARa (lanes 2 and 3)-transfected COS cell extracts. Equal
amounts ofbacterial lysates containing either the parent vector (pFL)
(lane 2) or the pFL-Z fusion protein (lane 3) were added together with
RARa-transfected COS cell extracts and incubated at 370C for 1 h to
promote heterodimerization. Lane 4 contains free probe. (B) RXRa
inhibits the binding of Z to the BMRF1 promoter. Mobility-shift
assays were done using the RRE probe and in vitro-translated Z.
Equal amounts of either purified GST (10 and 15 ug) alone (lanes 1
and 2, respectively) or purified GST-RXRa fusion protein (10 and 15
.g; lanes 3 and 4, respectively) were added with Z and incubated for
1 h before addition of the probe.
could bind to EaD probe (Fig. 4C). These results clearly
indicate that repression by Z of the BRE promoter does not
require direct DNA binding.
Z Interferes with RAR-Binding Activity. To test for poten-
tial physical interactions between RAR and Z, mobility-shift
assays were performed. The effect ofZ on the binding of the
RARa protein to its RARE motif was examined. The BRE
probe produced a specific complex that was more abundant
with pRshRARa-transfected extract than with the mock-
transfected extract (Fig. 5A, lanes 1 and 2). The amount of
this complex was greatly reduced when bacterial extract
containing the Z fusion protein (pFL-Z) was added to the
binding reaction mixture (Fig. 5A, lane 3), whereas an equal
amount of bacterial lysate expressing the pFlag vector alone
(lane 2) did not affect binding ofRARa to the BRE probe. As
a control, mobility-shift assays were performed using mock-
transfected COS-cell extracts and a probe containing se-
quences from the adenovirus major late promoter (29) (data
not shown). Addition of bacterially expressed Z had no effect
on the binding of major late transcription factor to this probe,
demonstrating the specificity of the inhibitory effect of Z on
the binding of RARa to its cognate site.
RXRa Interferes with Z Binding to the BMRF1 Promoter.
The effect of RXRa on binding of Z to the AP-1 motif in the
BMRF1 promoter was also examined. The addition of Z to
the RRE probe in which the RARE site of the BMRF1
promoter was abolished and, therefore, could not bind to
RXRa, produced a specific complex that was greatly reduced
when the RXRa fusion protein was added to the reaction
mixture (Fig. SB, lanes 3 and 4), whereas an equal amount of
eluted GST did not affect binding by Z to the RRE probe (Fig.
5B, lanes 1 and 2). In contrast, the RXRa protein did not
affect the level of SP1 binding to an SP1 probe (data not
shown). These results suggest that Z reduces binding of the
RAR protein to the RARE motif and that RXRa likewise
inhibits Z binding to the AP-1 motif.
Z and RXRa Proteins Interact Directly. The ability of the
GST-RXRa fusion protein to interact with Z protein (pFL-Z)
Z- Z
FIG. 6. Z and RXRa interact directly. For dimerization experi-
ments, 50 lAg of GST-fusion proteins bound to beads was incubated
with 32P-labeled pFL-Z protein (10,000 cpm) (30) in reaction buffer
for 1 h at 37°C, washed, pelleted, and boiled in Laemmli buffer.
Bound proteins were resolved by SDS/PAGE on 10%o gels and
visualized by autoradiography. The arrow indicates the position of
32P-labeled Z protein retained by fusion proteins GST-Z (lane 2) or
GST-RXRa (lane 3). Lane 1 contains GST alone. Molecular masses
in kDa are shown.
(22) was demonstrated using glutathione-linked Sepharose
beads. Labeled Z protein bound to GST-Z-coated beads (Fig.
6, lane 2) but did not interact with beads coated with GST
alone (lane 1). Labeled Z protein also bound to the GST-
RXRa fusion protein (lane 3). These results indicate that the
viral protein Z and the cellular protein RXRa directly interact
in the absence of their DNA-binding sites.
DISCUSSION
After primary infection EBV persists in the body as a
predominantly latent infection that is subject to episodic
reactivation. The molecular mechanism of viral reactivation
has been the subject of much study and has focused almost
exclusively on viral factors in the process. Although cellular
transcription factors contributing to reactivation phenomena
have been suspected, a major role for cellular factors that
may modulate the viral transactivation cascade has not been
proposed until now. In this report we present evidence that
the RARs may interact crucially with the viral protein that
triggers the initial step in viral reactivation. In the interaction
identified, the effect on viral reactivation is potentially neg-
ative or modulatory in nature.
The BMRF1 promoter is a prototypic EBV cytolytic cycle
promoter that contains an AP-1 site upstream of the tran-
scription start site and is transactivated by Z, an EBV
immediate-early protein that belongs to the basic leucine-
zipper family of proteins. Transactivation of the BMRF1
promoter by Z requires direct binding by Z to the AP-1 site
(4). In this study, we demonstrate that treatment with RA can
repress Z transactivation of BMRF1 promoter activity. We
show that a typical RARE resides adjacent to the AP-1 site
in the BMRF1 promoter and that both RXRa and RARa can
bind to this element very efficiently and inhibit Z-induced
transactivation of the BMRF1 promoter. However, RXRa-
induced repression does not require a functional RARE site
since RXRa inhibits Z-induced transactivation ofthe BMRF1
promoter even when this binding site is abolished.
The role of the RARE motif in the BMRF1 promoter is
unclear. The RARE may serve to increase the local concen-
tration of RXRa or RARa, thereby increasing the efficiency
of the Z-RXR or Z-RAR interaction. The existence of
multiple RARs and their differential tissue distribution, reg-
ulation, and developmentally determined expression suggest
that distinct receptors play different physiological roles (15).
In contrast to the inhibitory effect ofRXRa, it is possible that
another as yet unidentified RAR could actually be a positive
regulator of the BMRF1 promoter that could potentially
regulate it through a direct binding mechanism.
Differentiation-associated expression of Z has been de-
scribed in epithelial cells in cases of oral hairy leukoplakia. Z
appears to be expressed during the initial stages of differen-
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tiation and down-regulated at the later stages of differentia-
tion (31). The Z promoter, like the BMRF1 promoter, con-
tains upstream Z-binding sites and is autoregulated (2). It is
therefore possible that this differentiation-dependent expres-
sion of Z is regulated by differentiation-specific RARs.
Negative gene regulation by steroid hormone receptors is
thought to be mediated either by direct protein-protein
interaction or by competition for binding sites with positive
trans-acting factors (30, 32, 33). Several genes are negatively
regulated by RA through very different mechanisms. In two
promoters (stromelysin and collagenase), negative regulation
by RA is due to RARa-mediated inhibition of binding of the
Jun/Fos (AP-1) complex to its binding site (18, 19). In
contrast, negative regulation of the oxytocin promoter is
mediated through an estrogen response element. Cotransfec-
tion ofRAR and the oxytocin promoter antagonizes estrogen-
dependent stimulation of transcription of this promoter (21).
In the interleukin 2 promoter, which is positively regulated by
the Oct-i protein, RA induces down-regulation via an oc-
tamer motif (20). In this case, RA may affect signals activat-
ing the Oct-i protein function. Recently, RA has been shown
to negatively regulate the expression of the human papillo-
mavirus 18 E6/E7 genes via cis-elements located in the
central enhancer of the upstream regulatory region (34).
The finding reported here that RARa can negatively reg-
ulate transactivation by a basic leucine-zipper protein (Z) is
in some respects similar to the finding that RARa inhibits
AP-1-induced transactivation (18, 19). However, we now
demonstrate that the reciprocal effect can also occur,
namely, that a basic leucine-zipper protein (Z) can inhibit
RAR-induced transactivation. In addition, inhibition of Z
transactivator function is mediated by RXRa as well as
RARa.
Although a direct protein-protein interaction in vivo is the
simplest explanation of the results, there are other possibil-
ities. For example, it has been proposed that the Z protein
down-regulates glucocorticoid-mediated induction of the
EBV latent promoter Cp through an indirect mechanism
involving positive regulation of the c-fos promoter (35).
Similarly, Z could activate transcription of a cellular factor
that represses RAR induction of the cellular BRE promoter
or the RARs could activate a cellular factor repressing Z
function. Alternatively, Z and the RARs could interact indi-
rectly through a third cellular factor. In any event, the present
results suggest an interaction or "cross-coupling" between
viral and cellular proteins that may provide a mechanism for
abrogating Z-mediated transactivation of EBV genes in in-
fected cells, thus checking or modulating viral reactivation.
The results lead to the possibility that the cell differentiation
state mediated by RARs can affect viral reactivation and also
viral infection itself may affect the cell differentiation state
controlled by RARs.
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